.png){kind=icon}
Return
Tinea capitis: A current perspective
.png){kind=icon}
PRE
AI
DOI：10.1016/S0190-9622(00)90001-X.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
During the past 50 years, the predominant etiologic agent of tinea capitis in the United States and in Western Europe has changed from Microsporum audouinii to Trichophyton tonsurans. This is thought to be due in part to the sensitivity of M audouinii to griseofulvin treatment and, in part, due to the importing of T tonsurans by people emigrating from geographic areas where that vector had been the prominent cause of tinea capitis. With these changes, prospects for newer therapies with the novel antimycotic agents itraconazole, fluconazole, and terbinafine are reviewed.
Keywords:
ITRACONAZOLE PULSE THERAPY
ASYMPTOMATIC CARRIER STATE
TRICHOPHYTON-TONSURANS
ANTIFUNGAL AGENTS
DOUBLE-BLIND
SUPERFICIAL MYCOSES
SELENIUM SULFIDE
STRATUM-CORNEUM
HUMAN-SKIN
CHILDREN
Journal
IF:
11.8
Papers:
2.6W
Citations:
3.9W
Organization
No organization information available
Cited Papers
ShareSaveShareSaveShareSaveItraconazole - A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.png)
DRUGS
DRUGSIF14.4
PREAI
ShareSaveShareSaveShareSaveShareSave
View more